Importantly, our model (Fig. 1I) rendered the PI3K/Akt/mTOR pathway as an interesting target for an experimental therapy in models of HNPP and CMT1A. This evidence concerns the gene MTOR and hereditary neuropathy with liability to pressure palsies.